LU91429I9 - - Google Patents

Info

Publication number: LU91429I9
Authority: LU; Luxembourg

Application number

LU91429C

Other versions

LU91429I2 (fr

Inventor

Keith Biggadike

Steven John Coote

Rosalyn Kay Nice

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-05

Filing date

2008-04-16

Publication date

2019-01-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91429(I9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-08-05 Priority claimed from GBGB0019172.6A external-priority patent/GB0019172D0/en

2001-04-07 Priority claimed from GBGB0108800.4A external-priority patent/GB0108800D0/en

2008-04-16 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2008-06-16 Publication of LU91429I2 publication Critical patent/LU91429I2/fr

2019-01-02 Publication of LU91429I9 publication Critical patent/LU91429I9/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Diabetes (AREA)
Immunology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

LU91429C 2000-08-05 2008-04-16 "Furoate de fluticasone et ses solvates(AVAMYS)" LU91429I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0019172.6A GB0019172D0 (en)	2000-08-05	2000-08-05	Novel compounds
GBGB0108800.4A GB0108800D0 (en)	2001-04-07	2001-04-07	Novel compounds
PCT/GB2001/003495 WO2002012265A1 (fr)	2000-08-05	2001-08-03	6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYLE) OXY&excl;-11.BETA.-HYDROXY-16.ALPHA.-METHYLE-3-OXO-ANDROST-1,4,-DIENE-17-ACIDE CARBOTHIOIQUE S-FLUOROMETHYLE ESTER UTILISE COMME AGENT ANTI INFLAMMATOIRE

Publications (2)

Publication Number	Publication Date
LU91429I2 LU91429I2 (fr)	2008-06-16
LU91429I9 true LU91429I9 (fr)	2019-01-02

Family

ID=26244792

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU91429C LU91429I2 (fr)	2000-08-05	2008-04-16	"Furoate de fluticasone et ses solvates(AVAMYS)"

Country Status (36)

Country	Link
US (3)	US7498321B2 (fr)
EP (5)	EP2348032B1 (fr)
JP (3)	JP2004505990A (fr)
KR (3)	KR100889426B1 (fr)
CN (4)	CN1294141C (fr)
AP (1)	AP1422A (fr)
AR (3)	AR032471A1 (fr)
AT (2)	ATE380194T1 (fr)
AU (4)	AU7649701A (fr)
BG (1)	BG66241B1 (fr)
BR (2)	BR0113039A (fr)
CA (3)	CA2417826A1 (fr)
CO (2)	CO5310550A1 (fr)
CY (4)	CY1107899T1 (fr)
CZ (2)	CZ304043B6 (fr)
DE (3)	DE60131750T3 (fr)
DK (3)	DK2348032T3 (fr)
DZ (1)	DZ3468A1 (fr)
EA (1)	EA005992B1 (fr)
ES (4)	ES2317922T3 (fr)
FR (1)	FR08C0014I2 (fr)
HK (1)	HK1056181A1 (fr)
HU (3)	HUP0303084A2 (fr)
IL (4)	IL154175A0 (fr)
LU (1)	LU91429I2 (fr)
MA (1)	MA25899A1 (fr)
MX (2)	MXPA03001096A (fr)
NL (1)	NL300343I2 (fr)
NO (4)	NO20030550L (fr)
NZ (2)	NZ523957A (fr)
OA (1)	OA12394A (fr)
PL (2)	PL213373B1 (fr)
PT (3)	PT1775305E (fr)
SI (3)	SI1775305T1 (fr)
SK (1)	SK287576B6 (fr)
WO (2)	WO2002012266A1 (fr)

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6494079B1 (en)	2001-03-07	2002-12-17	Symyx Technologies, Inc.	Method and apparatus for characterizing materials by using a mechanical resonator
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
AR028948A1 (es)	2000-06-20	2003-05-28	Astrazeneca Ab	Compuestos novedosos
GB0019172D0 (en)	2000-08-05	2000-09-27	Glaxo Group Ltd	Novel compounds
US6787532B2 (en)	2000-08-05	2004-09-07	Smithkline Beecham Corporation	Formulation containing anti-inflammatory androstane derivatives
US6777399B2 (en) *	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
KR100889426B1 (ko) *	2000-08-05	2009-03-23	글락소 그룹 리미티드	항염증제로서의 6.알파.,9.알파.-디플루오로-17.알파.-'(2-푸라닐카르복실)옥시-11.베타.-히드록시-16.알파.-메틸-3-옥소-안드로스트-1,4-디엔-17-카르보티오산 ｓ-플루오로메틸 에스테르
US6750210B2 (en)	2000-08-05	2004-06-15	Smithkline Beecham Corporation	Formulation containing novel anti-inflammatory androstane derivative
US6777400B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
US6858593B2 (en) *	2000-08-05	2005-02-22	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
US6759398B2 (en)	2000-08-05	2004-07-06	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative
US6858596B2 (en)	2000-08-05	2005-02-22	Smithkline Beecham Corporation	Formulation containing anti-inflammatory androstane derivative
UA77656C2 (en)	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
AU2002253342B2 (en)	2001-04-30	2007-01-04	Glaxo Group Limited	Novel anti-inflammatory androstane derivatives
US7302830B2 (en)	2001-06-06	2007-12-04	Symyx Technologies, Inc.	Flow detectors having mechanical oscillators, and use thereof in flow characterization systems
JP2005500290A (ja) *	2001-06-12	2005-01-06	グラクソ　グループ　リミテッド	抗炎症性の、１７β−カルボチオアートアンドロスタン誘導体である１７α複素環エステル
GB0125259D0 (en) *	2001-10-20	2001-12-12	Glaxo Group Ltd	Novel compounds
US20030229058A1 (en) *	2001-11-13	2003-12-11	Moran Edmund J.	Aryl aniline beta2 adrenergic receptor agonists
GB0202216D0 (en) *	2002-01-31	2002-03-20	Glaxo Group Ltd	Novel compounds
AU2003244451A1 (en) *	2002-02-04	2003-09-02	Glaxo Group Limited	Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
EP1757281A3 (fr) *	2002-02-04	2009-07-15	Glaxo Group Limited	Formulation pour inhalation comprenant un glucocorticoïde et un agoniste de 2-adrénorécepteur béta
GB0202564D0 (en) *	2002-02-04	2002-03-20	Glaxo Group Ltd	Process
DE60321311D1 (de) *	2002-02-04	2008-07-10	Glaxo Group Ltd	Zubereitung zur inhalation enthaltend ein glucocorticoid und einen beta 2-adrenorezeptor agonisten
GB0202635D0 (en) *	2002-02-05	2002-03-20	Glaxo Wellcome Mfg Pte Ltd	Formulation containing novel anti-inflammatory androstane derivative
ES2425392T3 (es)	2002-03-20	2013-10-15	Mannkind Corporation	Cartucho para un aparato de inhalación
US6928877B2 (en)	2002-05-24	2005-08-16	Symyx Technologies, Inc.	High throughput microbalance and methods of using same
GB2389530B (en)	2002-06-14	2007-01-10	Cipla Ltd	Pharmaceutical compositions
US7043969B2 (en)	2002-10-18	2006-05-16	Symyx Technologies, Inc.	Machine fluid sensor and method
AU2003282936A1 (en)	2002-10-18	2004-05-04	Symyx Technologies, Inc.	Environmental control system fluid sensing system and method comprising a sesnsor with a mechanical resonator
IL153462A0 (en) *	2002-12-16	2003-07-06	Chemagis Ltd	Thiocarboxylic acid organic salts and processes utilizing the same
WO2004086027A2 (fr)	2003-03-21	2004-10-07	Symyx Technologies, Inc.	Resonateur mecanique
WO2004087731A1 (fr) *	2003-04-04	2004-10-14	Alpharma Aps	Methode de preparation de derives et d'intermediaires d'acides carbothioiques steroides
AR044519A1 (es)	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0316290D0 (en) *	2003-07-11	2003-08-13	Glaxo Group Ltd	Novel compounds
US20060263350A1 (en) *	2003-09-26	2006-11-23	Fairfield Clinical Trials Llc	Combination antihistamine medication
GB0323701D0 (en) *	2003-10-09	2003-11-12	Glaxo Group Ltd	Formulations
GB0324918D0 (en) *	2003-10-24	2003-11-26	Glaxo Group Ltd	Composition
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
ES2385934T3 (es)	2004-08-20	2012-08-03	Mannkind Corporation	Catálisis de la síntesis de dicetopiperazina.
HUE025151T2 (en)	2004-08-23	2016-01-28	Mannkind Corp	Diceto-piperazine salts for drug delivery
GT200500281A (es)	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0507165D0 (en) *	2005-04-08	2005-05-18	Glaxo Group Ltd	Novel crystalline pharmaceutical product
GB0507577D0 (en)	2005-04-14	2005-05-18	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
ES2265276B1 (es)	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200738634A (en)	2005-08-02	2007-10-16	Astrazeneca Ab	New salt
GB0516313D0 (en)	2005-08-08	2005-09-14	Argenta Discovery Ltd	Azole derivatives and their uses
US7994211B2 (en)	2005-08-08	2011-08-09	Argenta Discovery Limited	Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
US7799344B2 (en)	2005-09-14	2010-09-21	Mannkind Corporation	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
MY144906A (en)	2005-10-21	2011-11-30	Novartis Ag	Human antibodies against il13 and therapeutic uses
GB0521563D0 (en)	2005-10-21	2005-11-30	Glaxo Group Ltd	Novel compounds
AR058109A1 (es)	2005-12-20	2008-01-23	Glaxo Group Ltd	Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie
GB0526244D0 (en)	2005-12-22	2006-02-01	Novartis Ag	Organic compounds
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
US8039431B2 (en)	2006-02-22	2011-10-18	Mannkind Corporation	Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
JP2009530419A (ja) *	2006-03-22	2009-08-27	グラクソグループリミテッド	新規製剤
US20090123391A1 (en) *	2006-03-22	2009-05-14	3M Innovative Properties Company	Novel Formulations
MX2008013411A (es)	2006-04-20	2008-11-04	Glaxo Group Ltd	Nuevos compuestos.
RU2457209C2 (ru)	2006-04-21	2012-07-27	Новартис Аг	Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а
ES2296516B1 (es) *	2006-04-27	2009-04-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
GB0611587D0 (en)	2006-06-12	2006-07-19	Glaxo Group Ltd	Novel compounds
GB0612027D0 (en) *	2006-06-16	2006-07-26	Glaxo Group Ltd	Novel process
GB0615108D0 (en) *	2006-07-28	2006-09-06	Glaxo Group Ltd	Novel formulations
EP2046787B1 (fr)	2006-08-01	2011-04-06	Glaxo Group Limited	Composés de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de pde4
MX2009003185A (es)	2006-09-29	2009-04-03	Novartis Ag	Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
HRP20110201T1 (hr)	2007-01-10	2011-08-31	Irm Llc	Spojevi i sastavi kao inhibitori proteaze kanalizirane aktivacije
BRPI0806970A2 (pt)	2007-02-09	2014-04-08	Irm Llc	Compostos e composições como inibidores de protease de ativação de canal
ES2306595B1 (es) *	2007-02-09	2009-09-11	Laboratorios Almirall S.A.	Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
PE20081889A1 (es)	2007-03-23	2009-03-05	Smithkline Beecham Corp	Indol carboxamidas como inhibidores de ikk2
DE602008005140D1 (de)	2007-05-07	2011-04-07	Novartis Ag	Organische verbindungen
ES2320961B1 (es) *	2007-11-28	2010-03-17	Laboratorios Almirall, S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
AR069637A1 (es)	2007-12-10	2010-02-10	Novartis Ag	Derivados de pirazinas
TW200944540A (en)	2007-12-21	2009-11-01	Schering Corp	C20-C21 substituted glucocorticoid receptor agonists
CN101910153B (zh)	2008-01-11	2014-01-22	诺华股份有限公司	作为激酶抑制剂的嘧啶类
EP2096105A1 (fr) *	2008-02-28	2009-09-02	Laboratorios Almirall, S.A.	Dérivés de 4-(2-amino-1-hydroxyethyl)phénol en tant qu'antagonistes du récepteur adrénergique b2
US8268834B2 (en)	2008-03-19	2012-09-18	Novartis Ag	Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
MX2010012814A (es)	2008-05-23	2010-12-20	Amira Pharmaceuticals Inc	Inhibidor de proteina activadora de 5-lipoxigenasa.
WO2009147187A1 (fr)	2008-06-05	2009-12-10	Glaxo Group Limited	Dérivés de 4-carboxamide indazole utiles en tant qu'inhibiteurs de p13 kinases
WO2009150137A2 (fr)	2008-06-10	2009-12-17	Novartis Ag	Composés organiques
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
DK2293833T3 (en)	2008-06-13	2016-05-23	Mannkind Corp	DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
JP5479465B2 (ja)	2008-06-20	2014-04-23	マンカインドコーポレイション	吸入努力をリアルタイムにプロファイルする対話式機器および方法
US8148353B2 (en)	2008-08-07	2012-04-03	Plus Chemicals Sa	Polymorphs of fluticasone furoate and process for preparation thereof
US8236786B2 (en)	2008-08-07	2012-08-07	Pulmagen Therapeutics (Inflammation) Limited	Respiratory disease treatment
TWI494123B (zh)	2008-08-11	2015-08-01	Mannkind Corp	超快起作用胰島素之用途
WO2010025236A1 (fr) *	2008-08-27	2010-03-04	Alexander Goldin	Composition et procédé pour traiter le rhume
UY32297A (es)	2008-12-22	2010-05-31	Almirall Sa	Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
PL2379507T3 (pl)	2008-12-30	2014-03-31	Pulmagen Therapeutics Inflammation Ltd	Związki sulfonamidu do leczenia zaburzeń układu oddechowego
ES2433109T3 (es)	2009-01-13	2013-12-09	Glaxo Group Limited	Derivados de pirimidin-carboxamida como inhibidores de la Syk cinasa
PT2391366E (pt)	2009-01-29	2013-02-05	Novartis Ag	Benzimidazoles substituídos para o tratamento de astrocitomas
WO2010094643A1 (fr)	2009-02-17	2010-08-26	Glaxo Group Limited	Dérivés de quinoline et applications associées dans la rhinite et l'urticaire
PT3578169T (pt)	2009-02-26	2024-07-29	Glaxo Group Ltd	Formulações farmacêuticas compreendendo 4-{(1r)-2-[(2,6- diclorobenzil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2- (hidroximetil)fenol
WO2010102958A1 (fr)	2009-03-09	2010-09-16	Glaxo Group Limited	4-oxadiazol-2-yl-indazoles en tant qu'inhibiteurs des p13 kinases
US8354539B2 (en)	2009-03-10	2013-01-15	Glaxo Group Limited	Indole derivatives as IKK2 inhibitors
CA2754595C (fr)	2009-03-11	2017-06-27	Mannkind Corporation	Appareil, systeme et procede de mesure de resistance d'un inhalateur
EP2228368A1 (fr)	2009-03-12	2010-09-15	Almirall, S.A.	Procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-ph2nyl2thoxy)hexyl]amino}-1-hydroxy2thyl)-8-hydroxyquinolin-2(1h)-one
US20120058984A1 (en)	2009-03-17	2012-03-08	Catherine Mary Alder	Pyrimidine derivatives used as itk inhibitors
US20120016010A1 (en)	2009-03-19	2012-01-19	Merck Sharp & Dohme Corp	RNA Interference Mediated Inhibition of BTB and CNC Homology 1, Basic Leucine Zipper Transcription Factor 1 (BACH1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20100240629A1 (en) *	2009-03-19	2010-09-23	Adrienne Kovacsne-Mezei	Polymorphs of fluticasone furoate and processes for preparation thereof
US20120029054A1 (en)	2009-03-19	2012-02-02	Merck Sharp & Dohme Corp.	RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
US20120035247A1 (en)	2009-03-19	2012-02-09	Merck Sharp & Dohme Corp.	RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010107952A2 (fr)	2009-03-19	2010-09-23	Merck Sharp & Dohme Corp.	Inhibition médiée par arn interférence de l'expression génique de facteur de croissance de tissu conjonctif (ctgf) en utilisant un acide nucléique interférant court (ansi)
US20120022143A1 (en)	2009-03-27	2012-01-26	Merck Sharp & Dohme Corp	RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
WO2010111464A1 (fr)	2009-03-27	2010-09-30	Merck Sharp & Dohme Corp.	Inhibition par interférence arn de l'expression du gène kinase 1 de régulation du signal d'apoptose (ask1) au moyen d'un acide nucléique interférent court (ansi)
WO2010111468A2 (fr)	2009-03-27	2010-09-30	Merck Sharp & Dohme Corp.	INHIBITION PAR INTERFÉRENCE ARN DE L'EXPRESSION DU GÈNE DE LA CHAÎNE BÊTA DU FACTEUR DE CROISSANCE DES NERFS (NGFß) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (ANSI)
KR20110138223A (ko)	2009-03-27	2011-12-26	머크 샤프 앤드 돔 코포레이션	짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
EP2411019A2 (fr)	2009-03-27	2012-02-01	Merck Sharp&Dohme Corp.	Inhibition par interférence arn de l'expression du gène du signal transducteur et activateur de la transcription 1 (stat1) au moyen d'un acide nucléique interférent court (ansi)
PL2599778T3 (pl)	2009-04-23	2018-01-31	Theravance Respiratory Co Llc	Związki diamidowe mających działanie antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta 2
JP2012524754A (ja)	2009-04-24	2012-10-18	グラクソグループリミテッド	Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
AR076373A1 (es)	2009-04-24	2011-06-08	Glaxo Group Ltd	N-pirazolil carboxamidas como inhibidores de canales de calcio
PL2899191T3 (pl)	2009-04-30	2018-01-31	Glaxo Group Ltd	Indazole podstawione oksazolem jako inhibitory kinazy PI3
CN102448978A (zh)	2009-05-29	2012-05-09	辉瑞有限公司	新颖的糖皮质激素受体激动剂
US8551528B2 (en)	2009-06-12	2013-10-08	Mannkind Corporation	Diketopiperazine microparticles with defined specific surface areas
WO2010150014A1 (fr)	2009-06-24	2010-12-29	Pulmagen Therapeutics (Inflammation) Limited	Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt)	2009-08-12	2016-05-17	Novartis Ag	compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
PE20121148A1 (es)	2009-08-17	2012-09-07	Intellikine Llc	Compuestos heterociclicos y usos de los mismos
BR112012008061A2 (pt)	2009-08-20	2016-03-01	Novartis Ag	compostos de oxima heterocíclica
JP2013508414A (ja)	2009-10-22	2013-03-07	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症および他の慢性疾患の治療のための組成物
US9016147B2 (en)	2009-11-03	2015-04-28	Mannkind Corporation	Apparatus and method for simulating inhalation efforts
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
WO2011067365A1 (fr)	2009-12-03	2011-06-09	Glaxo Group Limited	Dérivés de benzpyrazole comme inhibiteurs des pi3 kinases
EP2507231A1 (fr)	2009-12-03	2012-10-10	Glaxo Group Limited	Dérivés d'indazole comme inhibiteurs des pi3-kinases
US20120238559A1 (en)	2009-12-03	2012-09-20	Glaxo Group Limited	Novel compounds
WO2011098746A1 (fr)	2010-02-09	2011-08-18	Pulmagen Therapeutics (Inflammation) Limited	Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone
GB201002243D0 (en)	2010-02-10	2010-03-31	Argenta Therapeutics Ltd	Respiratory disease treatment
GB201002224D0 (en)	2010-02-10	2010-03-31	Argenta Therapeutics Ltd	Respiratory disease treatment
WO2011110575A1 (fr)	2010-03-11	2011-09-15	Glaxo Group Limited	Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en)	2010-04-29	2010-06-16	Glaxo Group Ltd	Novel compounds
PT105138B (pt) *	2010-06-01	2012-11-06	Hovione Farmaciencia S A	Método para a preparação de compostos orgânicos monofluorometilados biologicamente activos
PT105139B (pt)	2010-06-01	2013-01-29	Hovione Farmaciencia S A	Método para a monofluorometilação de substratos orgânicos para preparação de compostos orgânicos biologicamente activos
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
EP2593444B1 (fr)	2010-07-15	2015-04-08	Battelle Memorial Institute	Polyols d'origine biologique pour utilisation potentielle en tant qu'ignifugeants dans des applications de polyuréthane et de polyester
WO2012025473A1 (fr)	2010-08-24	2012-03-01	Glaxo Group Limited	Antagonistes du récepteur 4 des chimiokines cc
WO2012025474A1 (fr)	2010-08-24	2012-03-01	Glaxo Group Limited	Composés indazole
EP3461474B1 (fr) *	2010-08-31	2020-11-11	GlaxoSmithKline Intellectual Property Development Limited	Produits médicamenteux pour inhalation sous forme de poudre sèche présentant propriétés de régulation d'humidité et leurs procédés d'administration
EP2611423B2 (fr)	2010-08-31	2022-09-21	GlaxoSmithKline Intellectual Property Development Limited	Produits médicamenteux pour inhalation sous forme de poudre sèche présentant propriétés de régulation d'humidité et leurs procédés d'administration
AU2014200770B2 (en) *	2010-08-31	2015-11-12	Glaxo Group Limited	Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
EP2611821A2 (fr) *	2010-09-01	2013-07-10	Cadila Healthcare Limited	Procédé pour préparer du fluticasone propionate/furoate
HUE026059T2 (en)	2010-09-08	2016-05-30	Glaxosmithkline Ip Dev Ltd	N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazol-6-yl ] Polymorphs and salts of 2 - (methyloxy) -3-pyridinyl] methanesulfonamide
US9326987B2 (en)	2010-09-08	2016-05-03	Glaxo Group Limited	Indazole derivatives for use in the treatment of influenza virus infection
WO2012034095A1 (fr)	2010-09-09	2012-03-15	Irm Llc	Composés et compositions comme inhibiteurs de trk
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en)	2010-09-17	2013-02-12	Novartis Ag	Pyrazine derivatives as enac blockers
WO2012035055A1 (fr)	2010-09-17	2012-03-22	Glaxo Group Limited	Nouveaux composés
AR083115A1 (es)	2010-09-30	2013-01-30	Theravance Inc	Sales oxalato cristalinas de un compuesto diamida
US9149462B2 (en)	2010-10-21	2015-10-06	Glaxo Group Limited	Pyrazole compounds acting against allergic, inflammatory and immune disorders
WO2012052458A1 (fr)	2010-10-21	2012-04-26	Glaxo Group Limited	Composés pyrazole agissant contre des états allergiques, immunitaires et inflammatoires
GB201018124D0 (en)	2010-10-27	2010-12-08	Glaxo Group Ltd	Polymorphs and salts
CN102558273B (zh)	2010-12-14	2014-07-02	浙江省天台县奥锐特药业有限公司	氟替卡松糠酸酯的制备方法
EP2673277A1 (fr)	2011-02-10	2013-12-18	Novartis AG	Composés de [1, 2, 4]triazolo [4, 3 -b]pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
JP5808826B2 (ja)	2011-02-23	2015-11-10	インテリカイン，エルエルシー	複素環化合物およびその使用
BR112013021638A2 (pt)	2011-02-25	2016-08-02	Irm Llc	"compostos inibidores de trk, seu uso e composições que os compreendem"
EP2683716A1 (fr)	2011-03-11	2014-01-15	Glaxo Group Limited	Dérivés pyrido[3,4-b]pyrazine en tant qu'inhibiteurs de syk
GB201104153D0 (en)	2011-03-11	2011-04-27	Glaxo Group Ltd	Novel compounds
MY180552A (en)	2011-04-01	2020-12-02	Mannkind Corp	Blister package for pharmaceutical cartridges
PT105723B (pt) *	2011-05-26	2014-03-24	Hovione Farmaci Ncia S A	Método para a preparação de compostos orgânicos biologicamente activos
BR112013031570A2 (pt)	2011-06-08	2017-03-21	Glaxo Group Ltd	inalador de pó seco.
US20140113888A1 (en)	2011-06-08	2014-04-24	Glaxo Group Limited	Novel Combination of Therapeutic Agents
WO2012174472A1 (fr)	2011-06-17	2012-12-20	Mannkind Corporation	Microparticules de dicétopipérazine de capacité élevée
UY34305A (es)	2011-09-01	2013-04-30	Novartis Ag	Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
EP2755976B1 (fr)	2011-09-15	2018-07-18	Novartis AG	3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituées en position 6 à activité tyrosine kinase
WO2013038373A1 (fr)	2011-09-16	2013-03-21	Novartis Ag	Dérivés pyrimidinamides
WO2013038378A1 (fr)	2011-09-16	2013-03-21	Novartis Ag	Dérivés pyridinamides
CN103946221B (zh)	2011-09-16	2016-08-03	诺华股份有限公司	用于治疗囊性纤维化的杂环化合物
ES2882807T3 (es)	2011-09-16	2021-12-02	Novartis Ag	Heterociclil carboxamidas N-sustituidas
WO2013038381A1 (fr)	2011-09-16	2013-03-21	Novartis Ag	Dérivés d'amide pyridine/pyrazine
EP2578570A1 (fr)	2011-10-07	2013-04-10	Almirall, S.A.	Nouveau procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one via de nouveaux intermédiaires de synthèse
EP2776053A1 (fr)	2011-10-24	2014-09-17	MannKind Corporation	Procédés et compositions pour traiter la douleur
US20130209543A1 (en)	2011-11-23	2013-08-15	Intellikine Llc	Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en)	2012-03-19	2014-08-19	Novartis Ag	Crystalline form
EP2641900A1 (fr)	2012-03-20	2013-09-25	Almirall, S.A.	Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
JP2015512425A (ja)	2012-04-03	2015-04-27	ノバルティスアーゲー	チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
CN104470503A (zh)	2012-04-13	2015-03-25	葛兰素史克知识产权开发有限公司	聚集粒子
SG11201500218VA (en)	2012-07-12	2015-03-30	Mannkind Corp	Dry powder drug delivery systems and methods
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
GB201222679D0 (en)	2012-12-17	2013-01-30	Glaxo Group Ltd	Pharmaceutical combination products
US9073921B2 (en)	2013-03-01	2015-07-07	Novartis Ag	Salt forms of bicyclic heterocyclic derivatives
AU2014228415B2 (en)	2013-03-15	2018-08-09	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
WO2014151147A1 (fr)	2013-03-15	2014-09-25	Intellikine, Llc	Combinaison d'inhibiteurs de kinase et ses utilisations
US10155001B2 (en)	2013-06-14	2018-12-18	Inserm (Institut National De La Sante Et De La Recherche Medicale)	RAC1 inhibitors for inducing bronchodilation
MX394255B (es)	2013-07-18	2025-03-24	Mannkind Corp	Composiciones farmaceuticas en polvo seco estables al calor y metodos
EP3030294B1 (fr)	2013-08-05	2020-10-07	MannKind Corporation	Appareil d'insufflation
WO2015055691A1 (fr)	2013-10-17	2015-04-23	Glaxosmithkline Intellectual Property Development Limited	Inhibiteur de pi3k pour le traitement d'une maladie respiratoire
CA2923995A1 (fr)	2013-10-17	2015-04-23	Glaxosmithkline Intellectual Property Development Limited	Inhibiteur de pi3k pour le traitement d'une maladie respiratoire
WO2015084804A1 (fr)	2013-12-03	2015-06-11	Novartis Ag	Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
EP3134396B1 (fr)	2014-04-24	2019-09-18	Novartis AG	Dérivés aminés de pyridine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
BR112016023967A2 (pt)	2014-04-24	2017-08-15	Novartis Ag	derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
CN106458979B (zh)	2014-04-24	2020-03-27	诺华股份有限公司	作为磷脂酰肌醇3-激酶抑制剂的氨基吡嗪衍生物
TW201625247A (zh)	2014-05-12	2016-07-16	葛蘭素史密斯克藍智慧財產權有限公司	用於治療傳染性疾病之醫藥組合物
US10987363B2 (en)	2014-05-28	2021-04-27	Glaxosmithkline Intellectual Property Development Limited	Fluticasone furoate in the treatment of COPD
WO2016011658A1 (fr)	2014-07-25	2016-01-28	Novartis Ag	Polythérapie
AU2015294889B2 (en)	2014-07-31	2018-03-15	Novartis Ag	Combination therapy
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
GB201602527D0 (en)	2016-02-12	2016-03-30	Glaxosmithkline Ip Dev Ltd	Chemical compounds
EP3497100A1 (fr)	2016-08-08	2019-06-19	GlaxoSmithKline Intellectual Property Development Limited	Composés chimiques
CN108066329B (zh) *	2016-11-11	2021-11-16	江苏恒瑞医药股份有限公司	一种吸入用氟替卡松或其衍生物的微粒的制备方法
GB201706102D0 (en)	2017-04-18	2017-05-31	Glaxosmithkline Ip Dev Ltd	Chemical compounds
GB201712081D0 (en)	2017-07-27	2017-09-13	Glaxosmithkline Ip Dev Ltd	Chemical compounds
TWI679279B (zh) *	2018-05-09	2019-12-11	臺中榮民總醫院	檢測成人發作型史笛兒氏症之罹病風險及預後之方法
SG11202012005VA (en)	2018-06-08	2021-01-28	Toko Yakuhin Kogyo Co Ltd	Fluticasone furoate nasal preparation composition
WO2019241580A1 (fr)	2018-06-14	2019-12-19	Astrazeneca Uk Limited	Méthodes de traitement et de prévention de symptômes de l'asthme au moyen d'une composition pharmaceutique de corticostéroïdes
CN111662353A (zh) *	2019-03-05	2020-09-15	上海谷森医药有限公司	一种糠酸氟替卡松晶型1的制备方法
AU2020290094B2 (en)	2019-06-10	2024-01-18	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
EP3999125A1 (fr) *	2019-07-17	2022-05-25	The Procter & Gamble Company	Compositions rafraîchissantes et méthodes de pulvérisation de compositions rafraîchissantes avec une cartouche microfluidique actionnée thermiquement
PE20220346A1 (es)	2019-08-28	2022-03-14	Novartis Ag	Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
WO2021041374A1 (fr)	2019-08-28	2021-03-04	Cai Gu Huang	Formulation liposomale de furoate de fluticasone et procédé de préparation
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
WO2021191875A1 (fr)	2020-03-26	2021-09-30	Glaxosmithkline Intellectual Property Development Limited	Inhibiteurs de cathepsine pour la prévention ou le traitement d'infections virales
JP2026501523A (ja) *	2023-01-10	2026-01-16	シチュアンケルン－バイオテックバイオファーマシューティカルカンパニーリミテッド	グルココルチコイド受容体アゴニスト及びそのコンジュゲート
CN117088932A (zh) *	2023-08-22	2023-11-21	黄冈人福药业有限责任公司	一种丙酸氟替卡松母液的处理方法
IT202300022716A1 (it) *	2023-10-30	2025-04-30	Ind Chimica Srl	Processo di condizionamento di fluticasone furoato micronizzato
WO2025105347A1 (fr) *	2023-11-16	2025-05-22	アルプス薬品工業株式会社	Composition, procédé de production d'ester d'acide furancarboxylique fluticasone, procédé de purification d'ester d'acide furancarboxylique fluticasone, et procédé de production d'un composé marqué
WO2025191309A1 (fr) *	2024-03-14	2025-09-18	Sterling S.P.A.	Procédé de précipitation contrôlée de furoate de fluticasone

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR580494A (fr)	1923-07-10	1924-11-07	Const Metalliques Schiltigheim	Procédé d'établissement des buses d'aération ou autres tuyaux
US2169265A (en)	1939-05-02	1939-08-15	City Novelty Corp	Linked ornamental chain
US2837464A (en)	1955-01-11	1958-06-03	Schering Corp	Process for production of dienes by corynebacteria
DE1059906B (de)	1954-10-05	1959-06-25	Scherico Ltd	Verfahren zur Herstellung von 1, 4-Pregnadienen
US2816902A (en) †	1957-01-14	1957-12-17	Schering Corp	Hydroxylated steroids
US3067197A (en)	1961-04-26	1962-12-04	Pfizer & Co C	11-oxygenated 6alpha-fluoro-16-methylene-delta-pregnenes and derivatives
GB1047518A (en)	1963-06-11	1966-11-02	Glaxo Lab Ltd	17ª-monoesters of 11,17,21-trihydroxy steroid compounds
GB1158492A (en)	1966-02-09	1969-07-16	Boots Pure Drug Co Ltd	Improvements in Acylated Steroids
US3639434A (en)	1967-02-02	1972-02-01	Boots Pure Drug Co Ltd	17-acyloxysteroids and their manufacture
IT1061787B (it)	1967-03-01	1983-04-30	Vismara Francesco Spa	Miglioramenti relativi alla preparazione di 17 benzoato di betametazone
GB1227992A (fr)	1968-01-23	1971-04-15	Koninklijke Gist Spiritus
IT1034011B (it)	1969-06-26	1979-09-10	Vister Vismara Terapeutici S P	Processo per la prapratzione di 17 monoesteri di 17 a 21 diossisteroidi per idrolisi die corpispondenti 17 21 ortoesteri ciclici a ph control lato
GB1384372A (en)	1971-01-20	1975-02-19	Glaxo Lab Ltd	Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids
BE788444A (fr) *	1971-09-06	1973-01-02	Sumitomo Chemical Co	Procede de production de 2,5-dimethyl-2,4-hexadiene
US3828080A (en) *	1972-01-20	1974-08-06	Glaxo Lab Ltd	Androstane-17beta-carboxylic acids and processes for the preparation thereof
US3808080A (en) *	1972-06-08	1974-04-30	Bronson Instr Inc	Ultrasonic seaming apparatus
US3989686A (en)	1972-06-15	1976-11-02	Glaxo Laboratories Limited	Anaesthetic steroids of the androstane series and process for preparing same
GB1438940A (en) *	1972-07-19	1976-06-09	Glaxo Lab Ltd	17beta-haloalkoxycarbonyl-17alpha-oxysteroids
GB1440063A (en)	1972-08-11	1976-06-23	Glaxo Lab Ltd	17alpha-esters of 17alpha,21-dihydroxy-20-oxo-steroids
DE2336693A1 (de)	1973-07-19	1975-02-06	Nassheuer Ind Ofenbau Jean	Strahlheizrohr
GB1517278A (en)	1974-08-30	1978-07-12	Glaxo Lab Ltd	Alkyl and haloalkyl androsta-1,4,15-triene and-4,15-diene-17beta-carboxylates
US4093721A (en)	1974-08-30	1978-06-06	Glaxo Laboratories Limited	Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
YU54476A (en)	1975-03-31	1982-05-31	Taisho Pharmaceutical Co Ltd	Process for obtaining 17-ester 21-halo-pregnane
DE2538569A1 (de)	1975-08-29	1977-03-03	Siemens Ag	Verfahren zur metallisierung von duroplasten
CH628355A5 (de)	1976-02-24	1982-02-26	Ciba Geigy Ag	Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
US4221787A (en)	1978-03-28	1980-09-09	Interx Research Corporation	Esteramide prodrugs of anti-inflammatory corticosteroids
US4188385A (en)	1978-04-05	1980-02-12	Syntex (U.S.A.) Inc.	Thioetianic acid derivatives
US4187301A (en)	1978-04-05	1980-02-05	Syntex (U.S.A.) Inc.	17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
US4263289A (en)	1978-04-05	1981-04-21	Syntex (U.S.A.) Inc.	Thio etianic acid derivatives
US4198403A (en)	1978-04-05	1980-04-15	Syntex (U.S.A.) Inc.	17 Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes
US4261984A (en)	1978-04-05	1981-04-14	Syntex (U.S.A.) Inc.	17β-thiocarboxylic acid esters of 3-oxo-4-halo-16β-methylandrost-4-enes
DE2817988A1 (de)	1978-04-25	1979-11-08	Hoechst Ag	Corticoid 17-alkylcarbonate und verfahren zu deren herstellung
US4310466A (en)	1979-08-31	1982-01-12	Syntex (U.S.A.) Inc.	Thio etianic acid derivatives
US4267173A (en)	1979-11-05	1981-05-12	Schering Corporation	Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor
CY1308A (en)	1979-12-06	1985-12-06	Glaxo Group Ltd	Device for dispensing medicaments
CY1291A (en)	1980-02-15	1985-10-18	Glaxo Group Ltd	Androstane 17 beta carbothioates
CA1201114A (fr) *	1980-02-15	1986-02-25	Gordon H. Phillipps	Carbothioates d'androstane
US4996335A (en)	1980-07-10	1991-02-26	Nicholas S. Bodor	Soft steroids having anti-inflammatory activity
ZA814440B (en)	1980-07-10	1982-10-27	Otsuka Pharma Co Ltd	Soft steroids having anti-inflammatory activity
US4710495A (en)	1980-07-10	1987-12-01	Otsuka Pharmaceutical Co., Ltd.	Soft steroids having anti-inflammatory activity
SE449106B (sv)	1980-07-10	1987-04-06	Otsuka Pharma Co Ltd	Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
EP0057401B1 (fr) *	1981-02-02	1984-08-01	Schering Corporation	Esters aromatiques hétérocycliques de stéroides, leur préparation et compositions pharmaceutiques les contenant
ATE23272T1 (de)	1981-07-08	1986-11-15	Draco Ab	Pulverinhalator.
GB2169265B (en)	1982-10-08	1987-08-12	Glaxo Group Ltd	Pack for medicament
ES286422Y (es)	1982-10-08	1986-09-16	Glaxo Group Limited	Dispositivo para administrar medicamentos a pacientes
ZW6584A1 (en)	1983-04-18	1985-04-17	Glaxo Group Ltd	Phenethanolamine derivatives
US4607028A (en)	1983-08-18	1986-08-19	Ciba-Geigy Corporation	Novel carboxylic acid esters
EP0179583A1 (fr)	1984-10-04	1986-04-30	Merck & Co. Inc.	Système pour augmenter la vitesse de dissolution dans l'eau et la solubilité de médicaments peu solubles
US4861765A (en)	1985-06-26	1989-08-29	Jouveinal	21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them
SE8603252L (sv)	1985-07-30	1987-01-31	Glaxo Group Ltd	Anordning for att tillfora lekemedel till patienter
ZA872389B (en)	1987-04-02	1987-11-25	Advanced Polymer Systems Inc	Composition and method for delivering a steroid active ingredient
ATE90355T1 (de)	1987-10-13	1993-06-15	Nicholas S Bodor	Weiche steroide mit anti-entzuendungswirkung.
US4994439A (en)	1989-01-19	1991-02-19	California Biotechnology Inc.	Transmembrane formulations for drug administration
FR2644787B1 (fr)	1989-03-22	1995-02-03	Roussel Uclaf	Nouveaux steroides 21 aminosubstitues, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
FR2644788B1 (fr)	1989-03-22	1995-02-03	Roussel Uclaf	Nouveaux steroides 3-ceto comportant une chaine en 17 amino-substituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
US5202316A (en)	1989-03-22	1993-04-13	Roussel Uclaf	N,N,N',N'-6-(1-piperazinyl)-2,5-pyridinediamines
JPH07116215B2 (ja)	1989-04-19	1995-12-13	エスエス製薬株式会社	新規なステロイド化合物
JPH04506066A (ja)	1989-06-16	1992-10-22	ジ・アップジョン・カンパニー	脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類
IL95590A (en) *	1989-09-08	1996-06-18	Glaxo Group Ltd	Medicinal preparations containing Salmetrol and Pluticasone Propionate
DE3931041C2 (de)	1989-09-16	2000-04-06	Boehringer Ingelheim Kg	Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
DE4025342A1 (de)	1990-08-10	1992-02-13	Hoechst Ag	In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
JP3087763B2 (ja)	1990-11-30	2000-09-11	三井化学株式会社	新規な複素環式化合物およびそれを含有する医薬組成物
GB9103764D0 (en)	1991-02-22	1991-04-10	Glaxo Group Ltd	Compositions
US5250293A (en)	1991-04-22	1993-10-05	Gleich Gerald J	Method for the treatment of hypersensitivity diseases by administration of anionic polymers
TW247878B (fr)	1991-07-02	1995-05-21	Takeda Pharm Industry Co Ltd
US6127353A (en)	1991-09-06	2000-10-03	Schering Corporation	Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5658549A (en)	1991-12-12	1997-08-19	Glaxo Group Limited	Aerosol formulations containing propellant 134a and fluticasone propionate
HU225869B1 (en)	1992-04-02	2007-11-28	Smithkline Beecham Corp	Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
AU679511B2 (en)	1993-03-17	1997-07-03	Minnesota Mining And Manufacturing Company	Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
DE4328819A1 (de) *	1993-08-27	1995-03-02	Hoechst Ag	Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE4333920A1 (de)	1993-10-05	1995-04-13	Hoechst Ag	Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US5420120A (en)	1993-12-17	1995-05-30	Alcon Laboratories, Inc.	Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
US5837699A (en)	1994-01-27	1998-11-17	Schering Corporation	Use of mometasone furoate for treating upper airway passage diseases
IL109656A (en)	1994-05-15	1998-02-22	Chemagis Ltd	Process for the manufacture of androstane - 17 - carbothioates and androstane - 17 - carbothioates prepared thereby
GB9410222D0 (en)	1994-05-21	1994-07-06	Glaxo Wellcome Australia Ltd	Medicaments
GB9419536D0 (en)	1994-09-28	1994-11-16	Glaxo Inc	Medicaments
SA95160463B1 (ar)	1994-12-22	2005-10-04	استرا أكتيبولاج	مساحيق للاستنشاق
JPH08291072A (ja)	1995-04-22	1996-11-05	Kissei Pharmaceut Co Ltd	吸入用粉末製剤用結晶とその製造方法
JPH08291073A (ja)	1995-04-22	1996-11-05	Kissei Pharmaceut Co Ltd	医薬品組成物及びその製造方法
DE19528145A1 (de)	1995-08-01	1997-02-06	Boehringer Ingelheim Kg	Neue Arzneimittel und ihre Verwendung
GB9521696D0 (en)	1995-10-23	1996-01-03	Bayer Ag	Combination of LTD4 receptor antagonists with glucocorticosteriods
US5792758A (en)	1995-12-08	1998-08-11	G. D. Searle & Co.	Steroid nitrite ester derivatives useful as anti-inflammatory drugs
US5707984A (en)	1995-12-08	1998-01-13	G. D. Searle & Co.	Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs
PT876392E (pt)	1995-12-29	2000-12-29	Glaxo Group Ltd	Derivados de lactona de derivados 17beta-carboxi carbotio e amida androstano
US5985862A (en)	1996-05-02	1999-11-16	G.D. Searle & Co.	Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
US5981517A (en)	1996-05-09	1999-11-09	Soft Drugs, Inc.	Androstene derivatives
JPH11511758A (ja)	1996-06-04	1999-10-12	ザ、プロクター、エンド、ギャンブル、カンパニー	鼻腔用ステロイドと抗ヒスタミン剤を含む鼻腔内噴霧薬
GB9622173D0 (en)	1996-10-24	1996-12-18	Glaxo Group Ltd	Particulate Products
US5919776A (en)	1996-12-20	1999-07-06	Merck & Co., Inc.	Substituted aminoquinolines as modulators of chemokine receptor activity
US6126919A (en)	1997-02-07	2000-10-03	3M Innovative Properties Company	Biocompatible compounds for pharmaceutical drug delivery systems
WO1998043630A1 (fr)	1997-04-02	1998-10-08	Brigham And Women's Hospital, Inc.	Moyen d'evaluation du profil a risque d'un individu pour les maladies atherosclereuses
ATE260931T1 (de)	1997-06-30	2004-03-15	Glaxo Group Ltd	Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität
AU9281298A (en)	1997-10-01	1999-04-23	Kyowa Hakko Kogyo Co. Ltd.	Benzodioxole derivatives
SE9704186D0 (sv)	1997-11-14	1997-11-14	Astra Ab	New composition of matter
SE9704833D0 (sv)	1997-12-22	1997-12-22	Astra Ab	New formulation
US5972920A (en)	1998-02-12	1999-10-26	Dermalogix Partners, Inc.	Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US6506766B1 (en)	1998-02-13	2003-01-14	Abbott Laboratories	Glucocortiocoid-selective antinflammatory agents
JP2002506856A (ja)	1998-03-14	2002-03-05	ビイクグルデンロンベルクヒエーミツシエフアブリークゲゼルシヤフトミツトベシユレンクテルハフツング	フタラジノンｐｄｅｉｉｉ／ｉｖ阻害剤
US6136294C1 (en)	1998-09-22	2002-09-24	Aeropharm Technology Inc	Amino acid stabilized medical aerosol formulation
US6261539B1 (en)	1998-12-10	2001-07-17	Akwete Adjei	Medicinal aerosol formulation
GB9828721D0 (en)	1998-12-24	1999-02-17	Glaxo Group Ltd	Novel apparatus and process
AU3703900A (en)	1999-02-24	2000-09-14	Nitromed, Inc.	Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
WO2000057401A1 (fr)	1999-03-24	2000-09-28	Glenayre Electronics, Inc.	Calcul et quantification de formes d'impulsions d'excitation voisees, dans le codage predictif de la parole
EP1175383B1 (fr)	1999-04-30	2018-03-14	Pfizer Products Inc.	Glucocorticoide recepteur modulateurs
US6395300B1 (en)	1999-05-27	2002-05-28	Acusphere, Inc.	Porous drug matrices and methods of manufacture thereof
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20020081266A1 (en)	1999-08-20	2002-06-27	Norton Healthcare Ltd.	Spray dried powders for pulmonary or nasal administration
EP1212101A1 (fr)	1999-08-31	2002-06-12	The Brigham And Women's Hospital, Inc.	Marqueurs inflammatoires systemiques en tant qu'outils diagnostiques dans la prevention des maladies atherosclereuses
US7413536B1 (en)	1999-09-14	2008-08-19	Xenoport, Inc.	Substrates and screening methods for transport proteins
US6596261B1 (en)	2000-01-25	2003-07-22	Aeropharm Technology Incorporated	Method of administering a medicinal aerosol formulation
JP2004501067A (ja)	2000-01-28	2004-01-15	ローム　アンド　ハース　カンパニー	高められた特性をもつ医薬
US20020133032A1 (en)	2000-02-25	2002-09-19	Jufang Barkalow	Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods
GB0009592D0 (en)	2000-04-18	2000-06-07	Glaxo Group Ltd	Respiratory combinations
GB0009591D0 (en)	2000-04-18	2000-06-07	Glaxo Group Ltd	Medical combinations
GB0009583D0 (en)	2000-04-18	2000-06-07	Glaxo Group Ltd	Respiratory formulations
GB0009606D0 (en)	2000-04-18	2000-06-07	Glaxo Group Ltd	Therapeutic combinations
GB0015876D0 (en)	2000-06-28	2000-08-23	Novartis Ag	Organic compounds
GB0016040D0 (en)	2000-06-29	2000-08-23	Glaxo Group Ltd	Novel process for preparing crystalline particles
GB0017988D0 (en)	2000-07-21	2000-09-13	Glaxo Group Ltd	Novel process
AU2001277891A1 (en)	2000-07-26	2002-02-05	Alcon Universal Ltd.	Pharmaceutical suspension compositions lacking a polymeric suspending agent
US6777399B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
US6858596B2 (en)	2000-08-05	2005-02-22	Smithkline Beecham Corporation	Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en)	2000-08-05	2004-09-07	Smithkline Beecham Corporation	Formulation containing anti-inflammatory androstane derivatives
US6750210B2 (en)	2000-08-05	2004-06-15	Smithkline Beecham Corporation	Formulation containing novel anti-inflammatory androstane derivative
GB0019172D0 (en)	2000-08-05	2000-09-27	Glaxo Group Ltd	Novel compounds
KR100889426B1 (ko)	2000-08-05	2009-03-23	글락소 그룹 리미티드	항염증제로서의 6.알파.,9.알파.-디플루오로-17.알파.-'(2-푸라닐카르복실)옥시-11.베타.-히드록시-16.알파.-메틸-3-옥소-안드로스트-1,4-디엔-17-카르보티오산 ｓ-플루오로메틸 에스테르
US6777400B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
US6759398B2 (en)	2000-08-05	2004-07-06	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative
US6858593B2 (en)	2000-08-05	2005-02-22	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
AR032362A1 (es)	2000-08-14	2003-11-05	Glaxo Group Ltd	Formulacion topica estable de una emulsion de aceite en agua y proceso para su preparacion
DE60124576T2 (de)	2000-09-29	2007-06-21	Glaxo Group Ltd., Greenford	Verbindungen verwendbar für die behandlung von entzündungskrankheiten
DE10062712A1 (de)	2000-12-15	2002-06-20	Boehringer Ingelheim Pharma	Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
AU2002210575A1 (en)	2000-10-31	2002-05-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Novel medicament compositions based on anticholinergics and corticosteroids
CA2438799C (fr)	2000-12-22	2009-09-01	Ssp Co., Ltd.	Agent prophylactique ou therapeutique ciblant les maladies respiratoires inflammatoires
US20020132803A1 (en)	2001-01-05	2002-09-19	Mahendra Dedhiya	Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
GB0103630D0 (en)	2001-02-14	2001-03-28	Glaxo Group Ltd	Chemical compounds
JP2004526720A (ja)	2001-03-08	2004-09-02	グラクソ　グループ　リミテッド	βアドレナリン受容体のアゴニスト
ATE381537T1 (de)	2001-03-22	2008-01-15	Glaxo Group Ltd	Formanilid-derivative als beta2-adrenorezeptor- agonisten
UA77656C2 (en)	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
AU2002303425A1 (en)	2001-04-24	2002-11-05	Epigenesis Pharmaceuticals, Inc.	Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
AU2002253342B2 (en)	2001-04-30	2007-01-04	Glaxo Group Limited	Novel anti-inflammatory androstane derivatives
JP2005500290A (ja)	2001-06-12	2005-01-06	グラクソ　グループ　リミテッド	抗炎症性の、１７β−カルボチオアートアンドロスタン誘導体である１７α複素環エステル
US20030018019A1 (en)	2001-06-23	2003-01-23	Boehringer Ingelheim Pharma Kg	Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DE10130371A1 (de)	2001-06-23	2003-01-02	Boehringer Ingelheim Pharma	Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
WO2003013427A2 (fr)	2001-08-03	2003-02-20	Smithkline Beecham Corporation	Procede de preparation de derives de fluticasone
GB0124523D0 (en)	2001-10-12	2001-12-05	Glaxo Group Ltd	Pharmaceutical combination
GB0125259D0 (en)	2001-10-20	2001-12-12	Glaxo Group Ltd	Novel compounds
WO2003040691A2 (fr)	2001-11-05	2003-05-15	The Brigham And Women's Hospital, Inc.	Cd40l(cd154) soluble en tant que marqueur pour le diagnostic de maladies d'atherosclerose
WO2003042229A1 (fr)	2001-11-12	2003-05-22	Glaxo Group Limited	Esters heterocycliques non aromatiques de furan-2-one esters de 17 $g(b) carboxyl ou 17 $g(b) carbothio glucocorticoides
GB0127160D0 (en)	2001-11-12	2002-01-02	Glaxo Group Ltd	Novel compounds
AU2002356759A1 (en)	2001-12-01	2003-06-17	Glaxo Group Limited	17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
WO2003072592A1 (fr)	2002-01-15	2003-09-04	Glaxo Group Limited	17 alpha esters cycloalkyle/cycloalcenyle d'alkyle ou haloalkyle-androst-4-en-3-on-11 beta, 17 alpha-diol 17 beta-carboxylates comme agents anti-inflammatoires
WO2003062259A2 (fr)	2002-01-21	2003-07-31	Glaxo Group Limited	Nouveaux composes
GB0202216D0 (en)	2002-01-31	2002-03-20	Glaxo Group Ltd	Novel compounds
JP3691459B2 (ja)	2002-06-14	2005-09-07	久光メディカル株式会社	粉末状吸入剤組成物
GB0217504D0 (en)	2002-07-29	2002-09-04	Novartis Ag	Organic compounds
DE10237739A1 (de)	2002-08-17	2004-02-26	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US7244742B2 (en)	2002-08-17	2007-07-17	Boehringer Ingelheim Pharma Gmbh & Co Kg	Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic

2001
- 2001-08-03 KR KR1020077028068A patent/KR100889426B1/ko not_active Expired - Lifetime
- 2001-08-03 NZ NZ523957A patent/NZ523957A/xx not_active IP Right Cessation
- 2001-08-03 ES ES01954149T patent/ES2317922T3/es not_active Expired - Lifetime
- 2001-08-03 EA EA200300082A patent/EA005992B1/ru not_active IP Right Cessation
- 2001-08-03 WO PCT/GB2001/003499 patent/WO2002012266A1/fr not_active Ceased
- 2001-08-03 EP EP10179104.4A patent/EP2348032B1/fr not_active Expired - Lifetime
- 2001-08-03 CA CA002417826A patent/CA2417826A1/fr not_active Abandoned
- 2001-08-03 CA CA002417825A patent/CA2417825C/fr not_active Expired - Lifetime
- 2001-08-03 NZ NZ523958A patent/NZ523958A/en unknown
- 2001-08-03 KR KR10-2003-7001671A patent/KR20030071751A/ko not_active Ceased
- 2001-08-03 CO CO01063015A patent/CO5310550A1/es active IP Right Grant
- 2001-08-03 PT PT71012694T patent/PT1775305E/pt unknown
- 2001-08-03 DE DE60131750.5T patent/DE60131750T3/de not_active Expired - Lifetime
- 2001-08-03 JP JP2002518239A patent/JP2004505990A/ja active Pending
- 2001-08-03 US US10/343,842 patent/US7498321B2/en not_active Expired - Fee Related
- 2001-08-03 CZ CZ20030352A patent/CZ304043B6/cs not_active IP Right Cessation
- 2001-08-03 CN CNB018166628A patent/CN1294141C/zh not_active Expired - Lifetime
- 2001-08-03 BR BR0113039-0A patent/BR0113039A/pt not_active IP Right Cessation
- 2001-08-03 IL IL15417501A patent/IL154175A0/xx unknown
- 2001-08-03 CZ CZ2003353A patent/CZ2003353A3/cs unknown
- 2001-08-03 DE DE60136818T patent/DE60136818D1/de not_active Revoked
- 2001-08-03 MX MXPA03001096A patent/MXPA03001096A/es active IP Right Grant
- 2001-08-03 CA CA002634715A patent/CA2634715A1/fr not_active Abandoned
- 2001-08-03 AU AU7649701A patent/AU7649701A/xx active Pending
- 2001-08-03 EP EP08020059A patent/EP2067784A3/fr not_active Withdrawn
- 2001-08-03 AR ARP010103734A patent/AR032471A1/es active IP Right Grant
- 2001-08-03 EP EP01954149A patent/EP1305330B1/fr not_active Revoked
- 2001-08-03 PL PL359999A patent/PL213373B1/pl unknown
- 2001-08-03 MX MXPA03001097A patent/MXPA03001097A/es not_active Application Discontinuation
- 2001-08-03 EP EP07101269.4A patent/EP1775305B1/fr not_active Expired - Lifetime
- 2001-08-03 ES ES07101269.4T patent/ES2523930T3/es not_active Expired - Lifetime
- 2001-08-03 CN CNB2005100670269A patent/CN100513416C/zh not_active Expired - Lifetime
- 2001-08-03 SI SI200131037T patent/SI1775305T1/sl unknown
- 2001-08-03 OA OA1200300023A patent/OA12394A/en unknown
- 2001-08-03 SI SI200130796T patent/SI1305329T2/sl unknown
- 2001-08-03 EP EP01953272.0A patent/EP1305329B2/fr not_active Expired - Lifetime
- 2001-08-03 DZ DZ013468A patent/DZ3468A1/fr active
- 2001-08-03 DE DE122008000029C patent/DE122008000029I1/de active Pending
- 2001-08-03 HK HK03106798.8A patent/HK1056181A1/zh unknown
- 2001-08-03 BR BRPI0113042-0 patent/BRPI0113042B8/pt not_active IP Right Cessation
- 2001-08-03 KR KR1020037001670A patent/KR100827379B1/ko not_active Expired - Lifetime
- 2001-08-03 JP JP2002518238A patent/JP4436041B2/ja not_active Expired - Lifetime
- 2001-08-03 PL PL01359917A patent/PL359917A1/xx not_active Application Discontinuation
- 2001-08-03 DK DK10179104.4T patent/DK2348032T3/en active
- 2001-08-03 WO PCT/GB2001/003495 patent/WO2002012265A1/fr not_active Ceased
- 2001-08-03 CO CO01063014A patent/CO5310534A1/es not_active Application Discontinuation
- 2001-08-03 SI SI200131046T patent/SI2348032T1/sl unknown
- 2001-08-03 AR ARP010103733A patent/AR032361A1/es unknown
- 2001-08-03 SK SK142-2003A patent/SK287576B6/sk not_active IP Right Cessation
- 2001-08-03 CN CNB2005100530367A patent/CN1315867C/zh not_active Expired - Fee Related
- 2001-08-03 AU AU7576001A patent/AU7576001A/xx active Pending
- 2001-08-03 AU AU2001276497A patent/AU2001276497B2/en not_active Ceased
- 2001-08-03 US US09/958,050 patent/US7101866B2/en not_active Expired - Lifetime
- 2001-08-03 HU HU0303084A patent/HUP0303084A2/hu unknown
- 2001-08-03 ES ES10179104.4T patent/ES2546830T3/es not_active Expired - Lifetime
- 2001-08-03 DK DK07101269.4T patent/DK1775305T3/da active
- 2001-08-03 AT AT01953272T patent/ATE380194T1/de active
- 2001-08-03 DK DK01953272.0T patent/DK1305329T4/da active
- 2001-08-03 AP APAP/P/2003/002731A patent/AP1422A/en active
- 2001-08-03 HU HU0303354A patent/HU230328B1/hu active Protection Beyond IP Right Term
- 2001-08-03 PT PT101791044T patent/PT2348032E/pt unknown
- 2001-08-03 AU AU2001275760A patent/AU2001275760B2/en not_active Expired
- 2001-08-03 PT PT01953272T patent/PT1305329E/pt unknown
- 2001-08-03 CN CNB018166644A patent/CN1294142C/zh not_active Expired - Fee Related
- 2001-08-03 ES ES01953272.0T patent/ES2292604T5/es not_active Expired - Lifetime
- 2001-08-03 AT AT01954149T patent/ATE416184T1/de not_active IP Right Cessation
- 2001-08-03 IL IL15414801A patent/IL154148A0/xx unknown
2003
- 2003-01-27 IL IL154148A patent/IL154148A/en active IP Right Grant
- 2003-02-04 BG BG107518A patent/BG66241B1/bg unknown
- 2003-02-04 NO NO20030550A patent/NO20030550L/no unknown
- 2003-02-04 NO NO20030549A patent/NO324747B1/no not_active IP Right Cessation
- 2003-02-05 MA MA27028A patent/MA25899A1/fr unknown
2007
- 2007-10-22 NO NO20075376A patent/NO333467B1/no not_active IP Right Cessation
- 2007-12-24 IL IL188364A patent/IL188364A/en active IP Right Grant
2008
- 2008-02-29 CY CY20081100241T patent/CY1107899T1/el unknown
- 2008-04-15 NL NL300343C patent/NL300343I2/nl unknown
- 2008-04-16 LU LU91429C patent/LU91429I2/fr unknown
- 2008-04-17 FR FR08C0014C patent/FR08C0014I2/fr active Active
- 2008-04-23 CY CY200800009C patent/CY2008009I2/el unknown
- 2008-05-28 NO NO2008006C patent/NO2008006I2/no not_active IP Right Cessation
- 2008-07-07 AR ARP080102929A patent/AR063555A1/es not_active Application Discontinuation
- 2008-08-28 US US12/199,991 patent/US20080317833A1/en not_active Abandoned
2009
- 2009-11-20 JP JP2009265248A patent/JP5150607B2/ja not_active Expired - Lifetime
2014
- 2014-12-05 CY CY20141101012T patent/CY1116145T1/el unknown
2015
- 2015-09-28 CY CY20151100853T patent/CY1116845T1/el unknown
2016
- 2016-03-11 HU HUS1600012C patent/HUS1600012I1/hu unknown

Also Published As

Publication number	Publication date
CN100513416C (zh)	2009-07-15
EP1305330A1 (fr)	2003-05-02
US20030199485A1 (en)	2003-10-23
CZ2003353A3 (cs)	2003-05-14
NZ523958A (en)	2004-11-26
JP5150607B2 (ja)	2013-02-20
CN1294142C (zh)	2007-01-10
IL188364A0 (en)	2008-03-20
HK1056180B (en)	2008-07-25
AU7649701A (en)	2002-02-18
US20080317833A1 (en)	2008-12-25
EA200300082A1 (ru)	2003-08-28
BR0113042A (pt)	2003-07-08
EP1305329B2 (fr)	2015-03-18
ES2546830T3 (es)	2015-09-29
ES2292604T5 (es)	2015-06-01
NO20030549D0 (no)	2003-02-04
PL359999A1 (en)	2004-09-06
CA2634715A1 (fr)	2002-02-14
DE60136818D1 (en)	2009-01-15
PT1775305E (pt)	2014-11-24
NO2008006I1 (no)	2008-06-23
NO2008006I2 (no)	2011-07-04
ES2292604T3 (es)	2008-03-16
JP2010077145A (ja)	2010-04-08
CN1680423A (zh)	2005-10-12
AU2001275760B2 (en)	2005-03-17
IL154148A (en)	2008-07-08
ES2523930T3 (es)	2014-12-02
NO324747B1 (no)	2007-12-03
PL359917A1 (en)	2004-09-06
JP4436041B2 (ja)	2010-03-24
PT2348032E (pt)	2015-10-14
SI2348032T1 (sl)	2015-10-30
BR0113039A (pt)	2003-07-15
AP2003002731A0 (en)	2003-03-31
CN1315867C (zh)	2007-05-16
LU91429I2 (fr)	2008-06-16
AR032471A1 (es)	2003-11-12
KR20070118317A (ko)	2007-12-14
MXPA03001096A (es)	2003-05-27
EP2348032A3 (fr)	2012-08-22
AR063555A1 (es)	2009-02-04
BG107518A (bg)	2003-09-30
CN1468252A (zh)	2004-01-14
BRPI0113042B8 (pt)	2021-05-25
SK1422003A3 (en)	2003-06-03
CZ304043B6 (cs)	2013-09-04
HK1056180A1 (en)	2004-02-06
PL213373B1 (pl)	2013-02-28
US7498321B2 (en)	2009-03-03
HUP0303354A3 (en)	2012-12-28
NO20030549L (no)	2003-02-04
NO333467B1 (no)	2013-06-17
US7101866B2 (en)	2006-09-05
NZ523957A (en)	2004-12-24
CY1116845T1 (el)	2017-03-15
CN1294141C (zh)	2007-01-10
PT1305329E (pt)	2007-12-24
CO5310550A1 (es)	2003-08-29
SI1305329T1 (sl)	2008-04-30
KR20030071751A (ko)	2003-09-06
MXPA03001097A (es)	2003-05-27
DK1775305T3 (en)	2014-11-17
EA005992B1 (ru)	2005-08-25
HUP0303354A2 (hu)	2004-01-28
KR100827379B1 (ko)	2008-05-07
EP1305330B1 (fr)	2008-12-03
EP1775305A2 (fr)	2007-04-18
DZ3468A1 (fr)	2002-02-14
WO2002012265A1 (fr)	2002-02-14
CO5310534A1 (es)	2003-08-29
DE60131750D1 (en)	2008-01-17
EP2348032A2 (fr)	2011-07-27
BRPI0113042B1 (pt)	2018-02-14
NO20075376L (no)	2007-10-22
JP2004505989A (ja)	2004-02-26
NL300343I1 (nl)	2008-06-02
EP1775305B1 (fr)	2014-09-17
DE60131750T2 (de)	2008-11-06
US20040028615A1 (en)	2004-02-12
SK287576B6 (sk)	2011-03-04
SI1305329T2 (sl)	2015-07-31
DK2348032T3 (en)	2015-08-24
AU2001276497B2 (en)	2005-04-07
EP2067784A3 (fr)	2012-08-22
EP1305329B1 (fr)	2007-12-05
JP2004505990A (ja)	2004-02-26
EP2348032B1 (fr)	2015-07-15
HK1056181A1 (zh)	2004-02-06
CN1468253A (zh)	2004-01-14
ATE380194T1 (de)	2007-12-15
NO20030550D0 (no)	2003-02-04
MA25899A1 (fr)	2003-10-01
FR08C0014I2 (fr)	2009-10-30
DE122008000029I1 (de)	2009-05-20
HU230328B1 (hu)	2016-02-29
CA2417826A1 (fr)	2002-02-14
ES2317922T3 (es)	2009-05-01
CY1107899T1 (el)	2010-07-28
AR032361A1 (es)	2003-11-05
FR08C0014I1 (fr)	2008-05-30
CY2008009I1 (el)	2009-11-04
IL154148A0 (en)	2003-07-31
HUP0303084A2 (hu)	2003-12-29
OA12394A (en)	2004-07-09
NO20030550L (no)	2003-04-04
AP1422A (en)	2005-06-05
KR100889426B1 (ko)	2009-03-23
DK1305329T4 (da)	2015-06-15
DE60131750T3 (de)	2015-07-30
KR20030028806A (ko)	2003-04-10
DK1305329T3 (da)	2008-02-04
CY1116145T1 (el)	2017-02-08
EP1775305A3 (fr)	2012-08-22
IL154175A0 (en)	2003-07-31
NL300343I2 (nl)	2008-09-01
CN1680425A (zh)	2005-10-12
ATE416184T1 (de)	2008-12-15
SI1775305T1 (sl)	2015-01-30
EP1305329A1 (fr)	2003-05-02
EP2067784A2 (fr)	2009-06-10
WO2002012266A1 (fr)	2002-02-14
AU7576001A (en)	2002-02-18
IL188364A (en)	2012-05-31
BG66241B1 (bg)	2012-08-31
CA2417825A1 (fr)	2002-02-14
HUS1600012I1 (hu)	2018-05-28
CA2417825C (fr)	2008-07-22
CY2008009I2 (el)	2009-11-04

Publication	Publication Date	Title
BE2014C019I2 (fr)	2021-01-29
BE2012C016I2 (fr)	2020-01-30
FR08C0014I1 (fr)	2008-05-30
BE2011C032I2 (fr)	2020-08-20
BE2010C018I2 (fr)	2020-08-20
BRPI0113085B8 (fr)	2021-05-25
JP2003507915A5 (fr)	2007-10-04
BE2011C041I2 (fr)	2020-08-20
JP2001165799A5 (fr)	2007-11-01
JP2001285747A5 (fr)	2006-12-28
JP2003510249A5 (fr)	2005-06-02
JP2003507713A5 (fr)	2007-10-04
JP2001068237A5 (fr)	2007-09-20
JP2003519089A5 (fr)	2005-11-17
JP2001350491A5 (fr)	2007-07-26
JP2002140082A5 (fr)	2007-12-06
JP2001302493A5 (fr)	2005-10-13
JP2002103610A5 (fr)	2006-03-02
JP2000298205A5 (fr)	2005-11-04
JP2002011387A5 (fr)	2007-06-21
JP2002082733A5 (fr)	2006-03-09
CN3144782S (fr)	2000-04-05
CN3141399S (fr)	2000-03-08
CN3159157S (fr)	2000-09-06
CN3139852S (fr)	2000-02-23